CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a $20.8 billion biotechnology company with a robust 75.6% gross profit margin, has reached a pivotal phase as regulatory agencies in the United States and ...

Explore groundbreaking gene-editing therapy for kidney disease, offering hope to those with polycystic kidney disease.

As Canada prepares for generic weight-loss drugs, the benefits for metabolic diseases come with weightier expectations that we should all be skinny ...

Objectives To develop a sustainable and accessible educational programme on biopsychosocial female-specific topics, for young female athletes in organised sport, their parents and coaches for future ...